New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
10:06 EDTAGN, VRXValeant sees FY15 cash EPS about $9.90 with deals, $9.40 with debt repayment
Valeant (VRX) sees FY15 cash EPS about $9.90 with deals, $9.40 with debt repayment. Valeant sees FY15 revenue about $9.7B with deals, $8.9B with debt repayment. Valeant laid out two alternate scenarios for its standalone projections, namely a debt repayment case and an acquisition case. Under the debt repayment scenario, leverage decreases to 2.9x in 2015 and 1.9x in 2016. Under the acquisition case, the company assumes acquisition of about $5B in 2015 and about $10B in 2016.
News For VRX;AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
09:18 EDTVRXValeant and Progenics' Relistor eceives positive opinion from EMA
Valeant (VRX) and Progenics (PGNX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for Relistor Subcutaneous Injection for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for Relistor, to 11 years from the date of approval.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use